2 completed, 1 recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow LPM3770164 sustained release tablet simulant: new trials by email Literature Review of LPM3770164 sustained release tablet simulant trials Research Report on LPM3770164 sustained release tablet simulant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia LPM3770164 sustained release tablet 5 mg, LPM3770164 sustained release tablet 10 mg, LPM3770164 sustained release tablet 20 mg - Tardive Dyskinesia (TD) | Phase 1 / Phase 2 | Recruiting | Luye Pharma Group Ltd. | 120 | 2025-01-14 | 2025-01-22 |
| Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant - Tardive Dyskinesia, Huntington Disease | Phase 1 | Completed | Luye Pharma Group Ltd. | 40 | 2023-12-19 | 2024-12-12 |
| A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant - Huntington Disease, Tardive Dyskinesia | Phase 1 | Completed | Luye Pharma Group Ltd. | 104 | 2022-02-25 | 2024-01-29 |
Tardive Dyskinesia (3) · Huntington Disease (2)
China (3)